International Tax Review is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Canadian Supreme Court decision on GlaxoSmithKline’s transfer pricing

The Canadian Supreme Court (SC) has today delivered its first transfer pricing decision, in a case involving GlaxoSmithKline (GSK).

gsk150.jpg

The SC dismissedthe appeal by the Canada Revenue Agency (CRA) of a ruling by the Federal Court concerning the deductibility of the price paid by GSK Canada to a Swiss related-entity. The CRA said the payment was not reasonable in the circumstances and a reasonable payment would have been that paid by generic companies.

GSK Canada said the consideration of reasonableness should take into account the licence agreement between the GSK group of companies and GSK Canada, which agreed a 6% royalty should be paid to the GSK group on sales of drugs covered by the agreement.

The trial judge ignored this and ruled the price GSK Canada should have paid was the highest of that paid by generic companies. This was overruled by the Federal Court in July 2010.

It has taken the SC judges 10 months to come to a decision after the hearing on January 13.

The SC held that the determination of an arm’s-length price must be informed by relevant surrounding economic circumstances, including other transactions that may be related to the purchasing transaction.

The case will now return to the Tax Court of Canada for redetermination because the SC also dismissed GSK’s cross-appeal, which asked it to overturn the decision of the Federal Court of Appeal to remit the matter to the Tax Court.

How GSK’s Canada SC hearing unfolded

Canadian Supreme Court confirms GSK date

GlaxoSmithKline files its arguments to Supreme Court of Canada

Supreme Court of Canada accepts Glaxo case

Glaxo prevails in the Canadian Federal Court of Appeal

Glaxo Canada: the key issues

Glaxo Canada loses transfer pricing case

more across site & bottom lb ros

More from across our site

The Brazilian government may be about to align the country’s unique system with OECD standards, but this is a long-awaited TP reform and success is uncertain.
Two months since EU political agreement on pillar two and few member states have made progress on new national laws, but the arrival of OECD technical guidance should quicken the pace. Ralph Cunningham reports.
It’s one of the great ironies of recent history that a populist Republican may have helped make international tax policy more progressive.
Lawmakers have up to 120 days to decide the future of Brazil’s unique transfer pricing rules, but many taxpayers are wary of radical change.
Shell reports profits of £32.2 billion, prompting calls for higher taxes on energy companies, while the IMF warns Australia to raise taxes to sustain public spending.
Governments now have the final OECD guidance on how to implement the 15% global minimum corporate tax rate.
The Indian company, which is contesting the bill, has a family connection to UK Prime Minister Rishi Sunak – whose government has just been hit by a tax scandal.
Developments included calls for tax reform in Malaysia and the US, concerns about the level of the VAT threshold in the UK, Ukraine’s preparations for EU accession, and more.
A steady stream of countries has announced steps towards implementing pillar two, but Korea has got there first. Ralph Cunningham finds out what tax executives should do next.
The BEPS Monitoring Group has found a rare point of agreement with business bodies advocating an EU-wide one-stop-shop for compliance under BEFIT.